American managed health care company and CVS Health subsidiary
Health-tech data sharing is advancing, with real-time interoperability and AI-assisted tools promised by CVS Health and partners. Meanwhile, lawsuits involving Epic and Health Gorilla highlight ongoing security gaps as regulators push for seamless sharing. Biometric risks from AI-fuelled fingerprint extraction add new concerns for consumer protection.
Foundayo, the oral GLP-1 weight-loss pill by Eli Lilly, has been authorised by the MHRA for weight management and type 2 diabetes. It will be available privately; NHS adoption depends on NICE evaluation. Several UK outlets report on uptake, pricing, side effects and competing pills, including Wegovy and Wegovy HD.
CVS Health has raised its 2026 guidance, citing stronger profits from its insurance and retail pharmacy segments and a marked improvement in its Aetna unit. The company is expanding GLP-1 weight-loss access through MinuteClinic, while flagging higher medical costs and macro risks.